Skip to search formSkip to main contentSkip to account menu

abarelix

Known as: N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N(6)-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide, abarelix [Chemical/Ingredient] 
A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Hormone AntagonistsOligopeptides

Narrower (2)

PPI-149Plenaxis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
Review
2006
Review
2006
Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.
Abarelix, a gonadotropin-releasing hormone antagonist, with its indication for advanced symptomatic prostate cancer, represents… 
Review
2004
Review
2004
Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues.
Review
2004
Review
2004
Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer
The high incidence of prostate cancer makes it a major healthcare problem and the second leading cancer-related cause of death… 
Highly Cited
2002
Highly Cited
2002
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer.
Highly Cited
2002
Highly Cited
2002
Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting… 
Highly Cited
2001
Highly Cited
2001
GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6.
A series of antagonists of gonadotropin-releasing hormone (GnRH) of the general formula Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph/4Amf(P… 
2001
2001
Luteinizing hormone-releasing hormone antagonists in prostate cancer.
Highly Cited
2001
Highly Cited
2001
A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.
Highly Cited
2000
Highly Cited
2000
Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.
PURPOSE A Phase II clinical study contrasted the endocrinologic and biochemical efficacy of Abarelix Depot, a gonadotropin… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)